JAK Inhibitors in Myelofibrosis

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Among 77 enrolled patients, the cumulative incidence of grades 2 to 4 aGVHD at day 100 post-transplantation was 18.2% (95% CI, 10.6–27.6%).

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Data from the 2025 EHA Congress show developments in novel therapeutic strategies across different multiple myeloma, leukemia, and lymphoma populations.

Read about various aspects of career trajectories in oncology from the perspective of established clinicians, new attendings, and those waiting to sit for their medical board exams.